Dr Bristi Basu
- CRUK Cambridge Centre: http://www.cambridgecancercentre.org.uk/users/bristi-basu
- Cambridge Pancreatic Cancer Centre: http://www.cambridge-pcc.org/team_bristi.html
My research focus is in drug development and I translate preclinical findings on lead candidate agents into early phase clinical trials of novel therapeutic drugs as chief investigator, principal investigator and co-investigator in academic-led and industry-sponsored Phase I, II and III clinical trials, including first-in-human studies. My tumour site-specific focus is in hepato-pancreatico-biliary cancers, for which I am designing novel clinical trials based on preclinical research that has been performed at the Cambridge Pancreatic Cancer Centre. I am involved in projects of non-invasive imaging techniques that evaluate pharmacodynamic effects or show potential as early predictors for efficacy of anticancer drugs.
First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor, AZD2014. B Basu*, E Dean*, M Puglisi, A Greystoke, M Ong, W Burke, M Cavallin, G Bigley, C Womack, E A Harrington, S Green, E Oelmann, J S de Bono, M Ranson, U Banerji. *Joint first authors Clin Cancer Res. 2015 Aug 1;21(15):3412-9. doi: 10.1158/1078-0432.CCR-14-2422
Combining Antiangiogenics to Overcome Resistance: rationale and clinical experience. V Moreno Garcia*, B.Basu*, R Molife, S Kaye. Clinical Cancer Research 2012 Jul 15; 18(14): 3750-61
Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain. B Basu, P Correa-Sampaio, H Mohammed, M Fogarasi, W English, N Watkins, P Corrie, W Ouwehand, G Murphy. International Journal of Biochemistry and Cell Biology 2012 Feb; 44(2): 393-403.
(*Joint first authors)